Pyonephrosis medical therapy

Jump to navigation Jump to search

Pyonephrosis Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pyonephrosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pyonephrosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pyonephrosis medical therapy

CDC on Pyonephrosis medical therapy

Pyonephrosis medical therapy in the news

Blogs on Pyonephrosis medical therapy

Directions to Hospitals Treating Pyonephrosis

Risk calculators and risk factors for Pyonephrosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Harsh Vardhan Chawla, M.B.B.S.[2]

Overview

Pyonephrosis is a surgical emergency. Hemodynamically unstable patients may require aggressive fluid resuscitation with crystalloids and pressor agent (dopamine) to maintain adequate blood pressure. All patients with pyonephrosis should be empirically treated with intravenous long-acting, broad-spectrum antibiotics like ampicillin + gentamicin combined with urgent drainage of the pus. After treating the infection, additional investigations are required to find the cause of the obstruction e.g., nephrolithiasis, tumors, etc. for definitive treatment.

Medical therapy

  • Pyonephrosis is a urological emergency.[1]
  • Hemodynamically unstable patients may require aggressive fluid resuscitation with crystalloids and pressor agent (dopamine) to maintain adequate blood pressure.
  • Before initiating antimicrobial treatment for suspected pyonephrosis, urine and blood culture and susceptibility test should always be performed.
  • All patients with pyonephrosis should be empirically treated with intravenous long-acting, broad-spectrum antibiotics which may be later narrowed based on culture report.
  • Presence of pyonephrosis and obstruction reduces the efficacy and penetration of antibiotics. Therefore, drainage of the pus should be done immediately after administering the antibiotics.
  • Intravenous Ampicillin + Gentamicin is a good initial option that covers both gram-positive and negative organisms.
  • Anaerobic coverage with clindamycin, antifungal, or antitubercular agents may be required depending upon the clinical scenario.
  • Carbapenem-resistant enterobacteriaceae can be treated with ceftazidime-avibactam, ceftolozane-tazobactam[2], meropenem-vaborbactam[3], and imipenem-cilastatin-relebactam.[4][5]
  • After treating the infection, additional investigations are required to find the cause of the obstruction e.g., nephrolithiasis, tumors, etc. for definitive treatment.

Antimicrobial Therapy

Antibiotics are started only after the sample has been drawn for urine and blood culture to identify the causative organisms and their antibiotic sensitivity. For pyonephrosis, treatment with IV antibiotics is continued until the patient is afebrile for 24-48 hours.[6] Rapid decompression with ureteral catheterization or nephrostomy drainage is warranted to prevent septic shock. Following this treatment, a 2-week course of PO regimen for uncomplicated pyelonephritis is also recommended.

  • Pyelonephritis empiric therapy[7]
  • Inpatient treatment

Refernces

  1. Ludvigson AE, Beaule LT (2016). "Urologic Emergencies". Surg Clin North Am. 96 (3): 407–24. doi:10.1016/j.suc.2016.02.001. PMID 27261785.
  2. Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO (2015). "Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)". Lancet. 385 (9981): 1949–56. doi:10.1016/S0140-6736(14)62220-0. PMID 25931244.
  3. Dhillon S (2018). "Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections". Drugs. 78 (12): 1259–1270. doi:10.1007/s40265-018-0966-7. PMC 6132495. PMID 30128699.
  4. Kuiper SG, Leegwater E, Wilms EB, van Nieuwkoop C (2020). "Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections". Expert Opin Pharmacother. 21 (15): 1805–1811. doi:10.1080/14656566.2020.1790525. PMID 32820669 Check |pmid= value (help).
  5. Doi Y (2019). "Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections". Clin Infect Dis. 69 (Suppl 7): S565–S575. doi:10.1093/cid/ciz830. PMC 6853760 Check |pmc= value (help). PMID 31724043.
  6. Hooton TM (2012). "Clinical practice. Uncomplicated urinary tract infection". N Engl J Med. 366 (11): 1028–37. doi:10.1056/NEJMcp1104429. PMID 22417256.
  7. Ng CK, Yip SK, Sim LS, Tan BH, Wong MY, Tan BS; et al. (2002). "Outcome of percutaneous nephrostomy for the management of pyonephrosis". Asian J Surg. 25 (3): 215–9. doi:10.1016/S1015-9584(09)60178-0. PMID 12376218.

Template:WH Template:WS